Vergoeding 2014-2018 voor ATC-subgroep G04BD : Middelen bij urge-incontinentie
- Raming voor de totale Zvw-populatie
| 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|
| G04BD02 Flavoxaat (Urispas ®) | 141.730 | 130.550 | 124.780 | 108.370 | 93.545 |
| G04BD04 Oxybutynine (Dridase ®) | 2.286.200 | 1.234.200 | 572.560 | 569.570 | 613.350 |
| G04BD07 Tolterodine (Detrusitol ®) | 681.730 | 537.470 | 474.420 | 459.730 | 536.450 |
| G04BD08 Solifenacine (Vesicare ®) | 13.397.300 | 13.283.900 | 13.485.900 | 12.889.000 | 12.483.500 |
| G04BD10 Darifenacine (Emselex ®) | 1.873.500 | 1.799.100 | 1.736.300 | 1.490.200 | 1.324.900 |
| G04BD11 Fesoterodine (Toviaz ®) | 1.746.000 | 1.542.900 | 1.477.400 | 1.373.600 | 1.277.000 |
| G04BD12 Mirabegron (Betmiga ®) | 1.296.400 | 2.990.000 | 3.549.900 | 4.349.300 | 5.127.400 |
| Totaal | 21.422.860 | 21.518.120 | 21.421.260 | 21.239.770 | 21.456.145 |